Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2026 | May 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2026 · Filed May 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,834 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 3,251 · Balance 9,834 F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005046 · doc4.xml · nonDerivative · entry 1 Davis Leslie C. · CIK 0002021765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,834 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004949 · doc4.xml · nonDerivative · entry 1 Davis Leslie C. · CIK 0002021765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,583 F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005892 · doc4.xml · nonDerivative · entry 1 Davis Leslie C. · CIK 0002021765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,055 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.